|
Written by Justine Cadet
ATLANTA--Ablative intervention was more effective than drug therapy for preventing recurrent symptomatic atrial fibrillation, according to the CABANA trial results presented Monday during a late-breaking clinical trial session at the American College of Cardiology’s (ACC) 59th annual conference. Slides»
A standard test of implantable cardioverter-defibrillators (ICDs) is linked to significant thought-processing problems that improve for most patients within a year after the device is inserted, according to a study published in the March 2 issue of Circulation: Arrhythmia and Electrophysiology.
Cardiovascular Consultants of Georgia has joined Piedmont Heart Institute, effective Jan. 29.
Written by Louis G. Lange, MD, PhD
Since the completion of the Human Genome Project in 2003, our understanding of the role played by genes in the development of disease has rapidly evolved from that of a single gene associated with relatively rare genetic conditions to multiple genes working in concert with environmental factors.
CardioNet, a wireless medical technology company focused on cardiac arrhythmias, has appointed Heather C. Getz to the position of senior vice president and chief financial officer (CFO), effective Jan. 15.
Bioniche Pharma, a developer of injectable pharmaceuticals, has launched ibutilide fumarate injection, the generic equivalent of Pfizer's antiarrhythmic drug Corvert .
The FDA has approved Stereotaxis’ Celsius RMT ThermoCool for use with the company’s magnetic navigation system for the treatment of type 1 atrial flutter.
Cardima, a medical device company, has received regulatory approval from the Japanese Ministry of Health, Labor and Welfare for its guidewire-based, multi-electrode diagnostic mapping catheter, Pathfinder.
With atrial fibrillation (AF) as the most widespread cardiac arrhythmia affecting patients, many new clinical trials are testing additional, more effective methods than the frequently prescribed drugs to treat AF, according to research published this month by the Millennium Research Group (MRG).
A multicenter study from Japan found that performing a microvolt T-wave alternans test on patients with left ventricular dysfunction accurately predicts whether patients have a risk for sudden cardiac death.
|
Monday, March 15, 8:00 AM to 9:30 AM
Who doesn’t love the “pearls and pitfalls” sessions? These are one of the best ways to get to the “heart” of a topic.
It was just a few years ago that papers were appearing describing the successful ablation of idiopathic outflow tract ventricular tachycardia from the distal great cardiac vein rather than the aortic cusp. While this might give EPs another option for treatment protocol, it’s still important to understand the challenges associated with the aortic valve cusp approach. That is just one of the topics that will be discussed in this session.
Use of an implantable leadless cardiac monitor in patients can better detect and monitor atrial fibrillation (AF) due to an algorithm that can detect the presence or absence of the heart arrhythmia, a study published online in the Feb. 16 issue of Circulation: Arrhythmia and Electrophysiology found.
A $3.5 million, three-and-a-half-year study, will gather data from 3,500 patients with implantable cardioverter-defibrillators (ICDs) to analyze the risks and benefits associated with ICDs in patients who are at risk of death from ventricular fibrillation.
The FDA has warned that a review of additional data indicates an increased risk of heart attack and stroke in patients with a history of cardiovascular disease using sibutramine (Meridia, Abbott Laboratories), a drug used to curb obesity and enhance weight loss.
Many more people could survive out-of-hospital cardiac arrest if regional systems of cardiac resuscitation care were established, according to an American Heart Association (AHA) policy statement published Jan. 14 in Circulation.
Asymptomatic atrial fibrillation (AF), compared with symptomatic patients, are more often older and at greater risk for thromboembolism and stroke, according to research presented by John Camm, MD, of the St. George’s University of London at the 15th annual Boston AF Symposium on Jan. 14.
Cardiac device developer Cambridge Heart has reportedly raised approximately $1.8 million in total capital from private placement, after a financial review of its Series D convertible preferred stock
Image quality of multi-detector CT scans, when utilized for the noninvasive detection of coronary artery stenosis, can be significantly associated with patient characteristics, including ethnicity, body mass index, heart rate and the presence of breathing artifact, but not with coronary artery calcium (CAC) score at a patient level, based on a study in the January issue of the American Journal of Roentgenology.
Research presented at the 2009 American Heart Association (AHA) scientific sessions in Orlando based on the subanalysis from the ADMIRE-HF phase III clinical trial suggested that imaging of the cardiac sympathetic nerves using the molecular imaging agent 123I-meta-iodobenzylguanidine (123I-MIBG, AdreView; GE Healthcare) may be useful in the assessment of risk for cardiac arrhythmias and cardiac death.
To better study treatments and patient outcomes linked to atrial fibrillation, the Duke Clinical Research Institute has initiated the Outcomes Registry for Better informed Treatment of Atrial Fibrillation.
|
RSS 
Middle age introduces itself in many ways; one is atrial fibrillation (AF). My onset of AF seems to have coincided with a mountain bike accident in the woods of North Carolina that resulted in some cracked ribs.
The use of health IT to reduce rehospitalizations will be welcome but also disruptive, said Stephen Jencks, an independent consultant in healthcare safety during a Feb. 24 webinar on the potential use of health IT to mitigate rehospitalizations, sponsored by the Agency for Healthcare Research and Quality (AHRQ).